Table I.
Descriptive characteristics of patient and control groups.
| Patient group | Control | Peritoneal dialysis | Hemodialysis | |
|---|---|---|---|---|
| Number of patients (n) | 40 | 44 | 44 | |
| Gender | Female (%) | 16 (40%) | 18 (43.3%) | 14 (33%) |
| Male (%) | 24 (60%) | 26 (56.7%) | 30 (67%) | |
| Age (years)(⎯x±s) | 43.9±8.5 | 45.8 ±13.3 | 48.2±12.3 | |
| BMI (kg/m2)(⎯x±s) | 27.7±3.7 | 29.7±3.9 | 28.7±4.1 | |
| Duration of initiating dialysis | <1year | – | 8 | 7 |
| 1–5 years | – | 25 | 28 | |
| 5–10 years | – | 11 | 9 | |
| Cigarette smoking (%) | 9 ( 24%) | 6 (13%) | 2 (4%) | |
| Disease information | Diabetes mellitus (%) | – | 8 (18%) | 5 (11%) |
| Bone diseases (%) | – | 5 (11%) | 6 (13%) | |
| Cardiovascular diseases (%) | – | 3 (8%) | 2 (4.5%) | |
| Hypertension (%) | – | 12 (27%) | 14 (31%) | |
| Dyslipidemia (%) | – | 6 (13%) | 8 (18%) | |
| Thyroid diseases (%) | – | 4 (9%) | – | |
| Drugs used | Anti-lipidemic (%) | – | 5 (11%) | 9 (16%) |
| Antihypertensive (%) | – | 29 (65%) | 17 (38%) | |
| T3 agonist | – | 4 (9%) | – | |
| Folic acid derivative (%) | - | 13 (29%) | 35 (79%) | |
| Iron drugs | – | 10 (22%) | 38 (86%) | |
| Phosphate binding | – | 13 (29%) | 41 (93%) | |
| Recombinant erythropoietin | – | 5 (11%) | 33 (75%) | |
| Anti-aggregant drugs | – | 3 (6.8%) | – | |